UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
AMENDMENT NO.2 to SCHEDULE 13G
Under the Securities Exchange Act of 1934
Nascent Biotech Inc.
(Name of Issuer)
Common Stock, with a par value $0.001 per share
(Title of Class of Securities)
63108Q101
(CUSIP Number)
December 31, 2023
(Date of Event, which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
¨ | Rule 13d-1(b) |
x | Rule 13d-1(c) |
¨ | Rule 13d-1(d) |
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information, which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act out shall be subject to all other provisions of the Act, (however, see the Notes).
Page 2
CUSIP No. 63108Q101
1. | Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)
YA II PN, Ltd. (98-0615462) | |
2. | Check the Appropriate Box if a Member of a
Group (See Instructions) (a) x (b) ¨ |
|
3. | SEC Use Only | |
4. | Citizenship or Place of Organization: Cayman
Islands
|
Number of Shares Beneficially Owned by Each Reporting Person With |
5. | Sole Voting Power: |
|
6 | Shared Voting Power: |
| |
7. | Sole Dispositive Power: |
| |
8. | Shared Dispositive Power: |
|
9. | Aggregate Amount Beneficially Owned by Each Reporting Person: | |
10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨ |
|
11. | Percentage of Class Represented by Amount in Row (9): | |
12. | Type of Reporting Person (See Instructions): OO |
Page 3
CUSIP No. 63108Q101
1. | Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)
YA Global Investments II (U.S.), LP (42-1766918) | |
2. | Check the Appropriate Box if a Member of a
Group (See Instructions) (a) x (b) ¨ |
|
3. | SEC Use Only | |
4. | Citizenship or Place of Organization: Delaware
|
Number of Shares Beneficially Owned by Each Reporting Person With |
5. | Sole Voting Power: |
|
6 | Shared Voting Power: |
| |
7. | Sole Dispositive Power: |
| |
8. | Shared Dispositive Power: |
|
9. | Aggregate Amount Beneficially Owned by Each Reporting Person: | |
10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨ |
|
11. | Percentage of Class Represented by Amount in Row (9): | |
12. | Type of Reporting Person (See Instructions): OO |
Page 4
CUSIP No. 63108Q101
1. | Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)
YA II GP, LP (80-0827189) | |
2. | Check the Appropriate Box if a Member of a
Group (See Instructions) (a) x (b) ¨ |
|
3. | SEC Use Only | |
4. | Citizenship or Place of Organization: Delaware
|
Number of Shares Beneficially Owned by Each Reporting Person With |
5. | Sole Voting Power: |
|
6 | Shared Voting Power: |
| |
7. | Sole Dispositive Power: |
| |
8. | Shared Dispositive Power: |
|
9. | Aggregate Amount Beneficially Owned by Each Reporting Person: | |
10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨ |
|
11. | Percentage of Class Represented by Amount in Row (9): | |
12. | Type of Reporting Person (See Instructions): OO |
Page 5
CUSIP No. 63108Q101
1. | Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)
YAII GP II, LLC (81-4908890) | |
2. | Check the Appropriate Box if a Member of a
Group (See Instructions) (a) x (b) ¨ |
|
3. | SEC Use Only | |
4. | Citizenship or Place of Organization: Delaware
|
Number of Shares Beneficially Owned by Each Reporting Person With |
5. | Sole Voting Power: |
|
6 | Shared Voting Power: |
| |
7. | Sole Dispositive Power: |
| |
8. | Shared Dispositive Power: |
|
9. | Aggregate Amount Beneficially Owned by Each Reporting Person: | |
10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨ |
|
11. | Percentage of Class Represented by Amount in Row (9): | |
12. | Type of Reporting Person (See Instructions): OO |
Page 6
CUSIP No. 63108Q101
1. | Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)
Yorkville Advisors Global, LP (90-0860458) | |
2. | Check the Appropriate Box if a Member of a
Group (See Instructions) (a) x (b) ¨ |
|
3. | SEC Use Only | |
4. | Citizenship or Place of Organization: Delaware
|
Number of Shares Beneficially Owned by Each Reporting Person With |
5. | Sole Voting Power: |
|
6 | Shared Voting Power: |
| |
7. | Sole Dispositive Power: |
| |
8. | Shared Dispositive Power: |
|
9. | Aggregate Amount Beneficially Owned by Each Reporting Person: | |
10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨ |
|
11. | Percentage of Class Represented by Amount in Row (9): | |
12. | Type of Reporting Person (See Instructions): OO |
Page 7
CUSIP No. 63108Q101
1. | Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)
Yorkville Advisors Global II, LLC (81-4918579) | |
2. | Check the Appropriate Box if a Member of a
Group (See Instructions) (a) x (b) ¨ |
|
3. | SEC Use Only | |
4. | Citizenship or Place of Organization: Delaware
|
Number of Shares Beneficially Owned by Each Reporting Person With |
5. | Sole Voting Power: |
|
6 | Shared Voting Power: |
| |
7. | Sole Dispositive Power: |
| |
8. | Shared Dispositive Power: |
|
9. | Aggregate Amount Beneficially Owned by Each Reporting Person: | |
10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨ |
|
11. | Percentage of Class Represented by Amount in Row (9): | |
12. | Type of Reporting Person (See Instructions): OO |
Page 8
CUSIP No. 63108Q101
1. | Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)
Mark Angelo
| |
2. | Check the Appropriate Box if a Member of a
Group (See Instructions) (a) x (b) ¨ |
|
3. | SEC Use Only | |
4. | Citizenship or Place of Organization: U.S.A.
|
Number of Shares Beneficially Owned by Each Reporting Person With |
5. | Sole Voting Power: |
|
6 | Shared Voting Power: |
| |
7. | Sole Dispositive Power: |
| |
8. | Shared Dispositive Power: |
|
9. | Aggregate Amount Beneficially Owned by Each Reporting Person: | |
10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨ |
|
11. | Percentage of Class Represented by Amount in Row (9): | |
12. | Type of Reporting Person (See Instructions): OO |
Page 9
This Amendment No. 2 is being filed by YA II PN, Ltd., YA Global Investments II (U.S.), Ltd., Yorkville Advisors Global, LP, Yorkville Advisors Global II, LLC, YA II GP, LP and YA II GP II, LLC (collectively, the “Reporting Persons”) and amends, supplements and supersedes, the initial Schedule 13G filed jointly by the Reporting Persons on August 31, 2022 (the “Original Schedule 13G”) and the 13G Amendment No. 1 filed jointly by the Reporting Persons on January 4, 2023. Except as specifically provided herein, this Amendment No. 2 does not modify any of the information previously reported in the Original Schedule 13G or Amendment No. 1. Capitalized terms in this Amendment No. 2 have the meanings assigned to them in the Original Schedule 13G and Amendment No. 1. This Amendment No. 2 is the final amendment to the Schedule 13G and constitutes an exit filing for the Reporting Persons
Item 1.
(a) | Name of Issuer: |
Nascent Biotech, Inc.
(b) | Address of Issuer’s Principal Executive Offices |
623 17th Street, Suite 4
Vero Beach, Florida 32960
Item 2. | Identity and Background. |
(a) | Name of Person Filing: |
YA II PN, Ltd.
(b) | Address of Principal Executive Office or, if none, Residence of Reporting Persons: |
1012 Springfield Ave.
Mountainside, NJ 07092
(c) | Citizenship: |
Cayman Islands
(d) | Title of Class of Securities: |
Common Stock, with a par value $0.001 per share
(e) | CUSIP Number: |
63108Q101
Item 3. | If the statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is: |
(a) | ¨ | Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o); | |
(b) | ¨ | Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c); | |
(c) | ¨ | Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c); | |
(d) | ¨ | Investment company registered under section 8 of the Investment Company Act of 1940 (15 of the Act (15 U.S.C. 78o); | |
(e) | ¨ | An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E); | |
(f) | ¨ | An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F); | |
(g) | ¨ | A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G); | |
(h) | ¨ | A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); | |
(i) | ¨ | A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); | |
(j) | ¨ | A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J); or | |
(k) | x | Group, in accordance with 240.13d(b)(1)(ii)(K). |
Page 10
Item 4. | Ownership |
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
(a) | Amount beneficially owned: |
(b) | Percentage of Class: |
(c) | Number of shares as to which the person has: |
(i) | Sole Power to vote or to direct the vote: 0 |
(ii) | Shared power to vote or to direct the vote: |
(iii) | Sole power to dispose or to direct the disposition: 0 |
(iv) | Shared power to dispose or to direct the disposition: |
Item 5. | Ownership of Five Percent or Less of a Class: |
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following x.
Page 11
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Dated: February 13, 2024 | ||
REPORTING PERSON: | ||
YA II PN, Ltd. | ||
By: | /s/ Robert Munro | |
Robert Munro | ||
Chief Compliance Officer | ||
YA Global Investments II (U.S.), Ltd. | ||
By: | /s/ Robert Munro | |
Robert Munro | ||
Chief Compliance Officer | ||
Yorkville Advisors Global, LP | ||
By: Yorkville Advisors Global, LLC | ||
Its: General Partner | ||
By: | /s/ Robert Munro | |
Robert Munro | ||
Chief Compliance Officer | ||
Yorkville Advisors Global II, LLC | ||
By: | /s/ Robert Munro | |
Robert Munro | ||
Chief Compliance Officer | ||
YA II GP, LP | ||
By: YAII GP II, LLC | ||
Its: General Partner | ||
By: | /s/ Robert Munro | |
Robert Munro | ||
Chief Compliance Officer | ||
YAII GP II, LLC | ||
By: | /s/ Robert Munro | |
Robert Munro | ||
Chief Compliance Officer |
EXHIBIT 99.1
JOINT FILING AGREEMENT
The undersigned hereby agree that the statement on Schedule 13G with respect to the equity securities of Nascent Biotech, Inc. is, and any amendment thereto signed by each of the undersigned shall be, filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended. The undersigned hereby further agree that this Joint Filing Agreement be included as an exhibit to such statement and any such amendment. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained herein and therein but shall not be responsible for the completeness and accuracy of the information concerning the others. This Joint Filing Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.
Dated: February 13, 2024
YA II PN, Ltd. | ||
By: | /s/ Robert Munro | |
Robert Munro | ||
Chief Compliance Officer | ||
YA Global Investments II (U.S.), Ltd. | ||
By: | /s/ Robert Munro | |
Robert Munro | ||
Chief Compliance Officer | ||
Yorkville Advisors Global, LP | ||
By: Yorkville Advisors Global, LLC | ||
Its: General Partner | ||
By: | /s/ Robert Munro | |
Robert Munro | ||
Chief Compliance Officer | ||
Yorkville Advisors Global II, LLC | ||
By: | /s/ Robert Munro | |
Robert Munro | ||
Chief Compliance Officer | ||
YA II GP, LP | ||
By: YAII GP II LLC | ||
Its: General Partner | ||
By: | /s/ Robert Munro | |
Robert Munro | ||
Chief Compliance Officer | ||
YAII GP II LLC | ||
By: | /s/ Robert Munro | |
Robert Munro | ||
Chief Compliance Officer |